{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT06877299",
      "orgStudyIdInfo": { "id": "IHC-003" },
      "organization": { "fullName": "Sichuan University", "class": "OTHER" },
      "briefTitle": "Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer",
      "officialTitle": "Low-Dose Radiation + Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy As Neoadjuvant Therapy in Patients with Resectable StageⅡA-ⅢB Non-small Cell Lung Cancer"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-03",
      "overallStatus": "NOT_YET_RECRUITING",
      "expandedAccessInfo": { "hasExpandedAccess": false },
      "startDateStruct": { "date": "2025-03-10", "type": "ESTIMATED" },
      "primaryCompletionDateStruct": {
        "date": "2027-07-01",
        "type": "ESTIMATED"
      },
      "completionDateStruct": { "date": "2028-01-01", "type": "ESTIMATED" },
      "studyFirstSubmitDate": "2025-03-10",
      "studyFirstSubmitQcDate": "2025-03-10",
      "studyFirstPostDateStruct": {
        "date": "2025-03-14",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2025-03-10",
      "lastUpdatePostDateStruct": {
        "date": "2025-03-14",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "You Lu",
        "investigatorTitle": "Chair of Division of Thoracic Tumor Multimodality Treatment",
        "investigatorAffiliation": "Sichuan University"
      },
      "leadSponsor": { "name": "Sichuan University", "class": "OTHER" }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.",
      "detailedDescription": "All eligible patients will receive LDRT combined with partial SBRT, followed by PD-1 inhibitors plus platinum-based chemotherapy, initiated within 7 days after completing radiation. PD-1 inhibitors and chemotherapy will be administered at the recommended doses according to the instruction manual every 3 weeks, with 3 cycles planned as neoadjuvant therapy. Surgery will be performed within 4 to 6 weeks (+7 days) after completing the final cycle of immunochemotherapy.\n\nMain objective and endpoint: the rate of pathological complete response (pCR) in the resected primary tumor and lymph nodes."
    },
    "conditionsModule": {
      "conditions": ["Lung Cancer", "Non-small Cell Lung Cancer"],
      "keywords": [
        "NSCNC",
        "Neoadjuvant",
        "Low Dose Radiotherapy",
        "Stereotactic Body Radiotherapy",
        "Immunotherapy"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": ["PHASE2"],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "interventionModelDescription": "Single Group Assignment",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": { "masking": "NONE" }
      },
      "enrollmentInfo": { "count": 30, "type": "ESTIMATED" }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Radiation therapy combined with PD-1 inhibitor and chemotherapy group",
          "type": "EXPERIMENTAL",
          "description": "Low-Dose Radiation(2Gy\\*2d) +Stereotactic body radiation therapy (10Gy\\*3d) followed by Tislelizumab (200mg) with platinum-based doublet chemotherapy administered pre-operatively every 3 weeks for 3 cycles before surgical resection.",
          "interventionNames": [
            "Drug: Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)",
          "description": "Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)",
          "armGroupLabels": [
            "Radiation therapy combined with PD-1 inhibitor and chemotherapy group"
          ],
          "otherNames": ["Drug: Tislelizumab", "Drug: Chemotherapy"]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "pCR rate",
          "description": "pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin stained slides of the resected lung specimen and lymph nodes following completion of neoadjuvant therapy",
          "timeFrame": "From date of enrollment until one month after resection"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "MPR rate",
          "description": "mPR is defined as ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes.",
          "timeFrame": "From date of enrollment until one month after resection"
        },
        {
          "measure": "R0-resection rate",
          "timeFrame": "From date of enrollment until one month after resection"
        },
        {
          "measure": "Event-free survival (EFS)",
          "description": "EFS is defined as the time from enrollment to radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause.",
          "timeFrame": "up to 2 years"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 75 years;\n2. Patients with untreated stage IIa-IIIB non-small cell lung cancer, diagnosed cytologically or histologically (according to the AJCC 9th edition of thoracic tumor staging);\n3. Pulmonary lesions will be assessed as resectable or potentially resectable by a multidisciplinary team, including a thoracic surgeon;\n4. At least one imaging-measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1);\n5. Ability to provide tumor tissue or cell wax blocks that meet quality control standards for PD-L1 expression testing.\n\nExclusion Criteria:\n\n1. The pathology is small cell lung cancer (SCLC), including lung cancer mixed with SCLC and non-small cell lung cancer (NSCLC)；\n2. Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T cell receptors;\n3. Subjects with any known or suspected autoimmune disorder or immunodeficiency, with the following exceptions: hypothyroidism, hormone therapy is not needed, or well controlled at physiological dose; controlled type I diabetes;\n4. Active infection requiring systemic treatment.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "75 Years",
      "stdAges": ["ADULT", "OLDER_ADULT"]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Jianxin Xue, MD. Phd",
          "role": "CONTACT",
          "phone": "18982251798",
          "email": "killercell@163.com"
        },
        {
          "name": "You Lu, MD. PhD",
          "role": "CONTACT",
          "phone": "+86 189 8060 1763",
          "email": "radyoulu@hotmail.com"
        }
      ],
      "overallOfficials": [
        {
          "name": "You Lu, MD. PhD",
          "affiliation": "Study Principal Investigator",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "West China Hospital of Sichuan University",
          "city": "Chengdu",
          "zip": "610041",
          "country": "China",
          "geoPoint": { "lat": 30.66667, "lon": 104.06667 }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "37581611",
          "type": "BACKGROUND",
          "citation": "Zhou X, Zhou L, Yao Z, Huang M, Gong Y, Zou B, Zhu J, Liu Y, Peng F, Zhang Y, Yu M, Li Y, Na F, Wu Y, Kang K, Xiu W, Zhang X, Zhou L, Xu Y, Wang J, Wang Y, Yang X, Wu Y, Li R, Zhang Y, Yang Z, Zhou Z, Bai J, Yi X, Tong R, Yin L, Chen C, Niedermann G, Lu Y, Xue J. Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 2023 Oct 13;29(20):4098-4108. doi: 10.1158/1078-0432.CCR-23-0315."
        },
        {
          "pmid": "32417411",
          "type": "BACKGROUND",
          "citation": "Yin L, Xue J, Li R, Zhou L, Deng L, Chen L, Zhang Y, Li Y, Zhang X, Xiu W, Tong R, Gong Y, Huang M, Xu Y, Zhu J, Yu M, Li M, Lan J, Wang J, Mo X, Wei Y, Niedermann G, Lu Y. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):212-224. doi: 10.1016/j.ijrobp.2020.05.002. Epub 2020 May 15."
        },
        {
          "pmid": "39305910",
          "type": "BACKGROUND",
          "citation": "Zhao ZR, Liu SL, Zhou T, Chen G, Long H, Su XD, Zhang X, Fu JH, Lin P, Zhang LJ, Rong TH, Wu JD, Li ZC, Su HL, Chen JY, Yang YP, Lin YB, Xi M, Yang H. Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial. Lancet Respir Med. 2024 Dec;12(12):988-996. doi: 10.1016/S2213-2600(24)00215-7. Epub 2024 Sep 18."
        },
        {
          "pmid": "39581197",
          "type": "BACKGROUND",
          "citation": "Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Cheng Y, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Yao B, Wang S, Wang RH, Zheng W, Wang C; RATIONALE-315 investigators. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Respir Med. 2025 Feb;13(2):119-129. doi: 10.1016/S2213-2600(24)00269-8. Epub 2024 Nov 21."
        },
        {
          "pmid": "35403841",
          "type": "BACKGROUND",
          "citation": "Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11."
        }
      ]
    },
    "ipdSharingStatementModule": { "ipdSharing": "NO" }
  },
  "derivedSection": {
    "miscInfoModule": { "versionHolder": "2025-03-19" },
    "conditionBrowseModule": {
      "meshes": [
        { "id": "D008175", "term": "Lung Neoplasms" },
        { "id": "D002289", "term": "Carcinoma, Non-Small-Cell Lung" }
      ],
      "ancestors": [
        { "id": "D012142", "term": "Respiratory Tract Neoplasms" },
        { "id": "D013899", "term": "Thoracic Neoplasms" },
        { "id": "D009371", "term": "Neoplasms by Site" },
        { "id": "D009369", "term": "Neoplasms" },
        { "id": "D008171", "term": "Lung Diseases" },
        { "id": "D012140", "term": "Respiratory Tract Diseases" },
        { "id": "D002283", "term": "Carcinoma, Bronchogenic" },
        { "id": "D001984", "term": "Bronchial Neoplasms" }
      ],
      "browseLeaves": [
        {
          "id": "M11172",
          "name": "Lung Neoplasms",
          "asFound": "Lung Cancer",
          "relevance": "HIGH"
        },
        {
          "id": "M5546",
          "name": "Carcinoma, Non-Small-Cell Lung",
          "asFound": "Non-small Cell Lung Cancer",
          "relevance": "HIGH"
        },
        { "id": "M5534", "name": "Carcinoma", "relevance": "LOW" },
        {
          "id": "M14979",
          "name": "Respiratory Tract Neoplasms",
          "relevance": "LOW"
        },
        { "id": "M16658", "name": "Thoracic Neoplasms", "relevance": "LOW" },
        { "id": "M11168", "name": "Lung Diseases", "relevance": "LOW" },
        {
          "id": "M14977",
          "name": "Respiratory Tract Diseases",
          "relevance": "LOW"
        },
        {
          "id": "M5540",
          "name": "Carcinoma, Bronchogenic",
          "relevance": "LOW"
        },
        { "id": "M5260", "name": "Bronchial Neoplasms", "relevance": "LOW" }
      ],
      "browseBranches": [
        { "abbrev": "BC04", "name": "Neoplasms" },
        {
          "abbrev": "BC08",
          "name": "Respiratory Tract (Lung and Bronchial) Diseases"
        },
        { "abbrev": "All", "name": "All Conditions" }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [{ "id": "C000707970", "term": "Tislelizumab" }],
      "ancestors": [
        {
          "id": "D000074322",
          "term": "Antineoplastic Agents, Immunological"
        },
        { "id": "D000970", "term": "Antineoplastic Agents" }
      ],
      "browseLeaves": [
        {
          "id": "M137899",
          "name": "Tislelizumab",
          "asFound": "Stable",
          "relevance": "HIGH"
        },
        {
          "id": "M2853",
          "name": "Immunomodulating Agents",
          "relevance": "LOW"
        },
        {
          "id": "M1346",
          "name": "Antineoplastic Agents, Immunological",
          "relevance": "LOW"
        }
      ],
      "browseBranches": [
        { "abbrev": "ANeo", "name": "Antineoplastic Agents" },
        { "abbrev": "All", "name": "All Drugs and Chemicals" }
      ]
    }
  },
  "hasResults": false
}
